

## APPENDIX

### AMENDMENT TO THE CLAIMS

Please cancel nonelected Claims 1-9 and 18 as follows:

Claims 1-9 (Canceled).

Claim 10 (Previously presented): A method for protecting a porcine animal against disease caused by *Mycoplasma hyopneumoniae* comprising the step of administering to said porcine animal a vaccine composition which comprises an immunizing amount of a *Mycoplasma hyopneumoniae* bacterin; an adjuvant mixture comprising a polyacrylic acid polymer and a mixture of metabolizable oil and a polyoxyethylene-polypropylene block copolymer; a pharmaceutically acceptable carrier which vaccine composition, after a single administration elicits protective immunity from *Mycoplasma hyopneumoniae* infection; and wherein the step of administering to said porcine animal is done by a method chosen from the group consisting of, intramuscular injection, subcutaneous injection, oral administration and nasal administration.

Claim 11 (Previously presented): The method of claim 10, wherein the immunizing amount of said bacterin is about  $1 \times 10^8$  to  $3 \times 10^{11}$  *Mycoplasma hyopneumoniae* DNA Cell equivalents, (MHDCE/mL).

Claim 12 (Previously presented): The method according to claim 11 wherein the immunizing amount of said bacterin is about  $1 \times 10^9$  to  $3 \times 10^9$  MHDCE/mL.

Claim 13 (Canceled).

Claim 14 (Original): The method of claim 10, wherein the adjuvant mixture consists of a polyacrylic acid polymer and a mixture of metabolizable oil that comprises one or more terpene hydrocarbons and a polyoxyethylene-polypropylene block copolymer present in a final concentration of about 1-25% v/v.

Claim 15 (Previously presented): The method of claim 14, wherein the polyacrylic acid polymer of the adjuvant mixture is CARBOPOL.

Claim 16 (Previously presented): The method of claim 14, wherein the metabolizable oil of the adjuvant mixture is a terpene hydrocarbon selected from the group consisting of squalene and squalane.

Claim 17 (Previously presented): The method of any claims 10-16, further comprising coadministering at least one additional bacterin selected from the group consisting of *Haemophilus parasuis*; *Pasteurella multocida*; *Streptococcus suis*; *Actinobacillus pleuropneumoniae*; *Bordetella bronchiseptica*; *Salmonella choleraesuis*; and leptospira.

Claim 18 (Canceled).